Lantheus Holdings

Lantheus sells radiopharmaceuticals — radioactive compounds injected into patients to illuminate disease during PET or SPECT scans. Its dominant product is DEFINITY, an ultrasound contrast agent used in roughly 4 million echocardiograms annually in the U.S. PYLARIFY, a prostate cancer imaging agent launched in 2021, is the fastest-growing radiopharmaceutical in commercial history and generated over $850 million in 2023 revenue alone. The firm also sells TechneLite, a generator system producing technetium-99m used in over 20,000 U.S. hospital nuclear medicine departments daily.

The company owns multiple cyclotron production facilities that irradiate raw material to produce short-lived isotopes like fluorine-18 for PYLARIFY, then delivers them through its own radiopharmacy network because the product decays within hours. For DEFINITY, the contrast agent contains perflutren microspheres that must be activated via mechanical agitation before injection — a distinct supply chain from traditional pharmaceuticals. The firm also relies on third-party reactor-based sources for molybdenum-99, the parent isotope of technetium-99m.

In cardiac imaging, GE HealthCare is the primary competitor for stress agents. Siemens Healthineers competes across several PET imaging categories. Bracco Diagnostics markets a directly competing ultrasound contrast agent, Lumason, though DEFINITY holds a larger U.S. market share. In prostate cancer imaging, Novartis (through its Advanced Accelerator Applications division) and Telix Pharmaceuticals have launched competing PSMA-targeted products. The U.S. radiopharmaceutical market is consolidated, with roughly five companies controlling over 80% of commercial distribution.

No. Lantheus is a publicly traded commercial company listed on Nasdaq under ticker LNTH. It was never a family office, investment partnership, or pooled capital vehicle. The firm was originally the internal medical imaging division of DuPont, spent decades as a Bristol-Myers Squibb subsidiary, and was spun out via an IPO in 2015. It operates as a conventional for-profit corporation with pharmaceutical manufacturing and distribution facilities, not as an allocator of third-party capital.

The company makes targeted acquisitions of clinical-stage radiopharmaceutical assets rather than diversified pharma portfolios. The 2020 Progenics Pharmaceuticals acquisition ($411 million) added oncology imaging agents, including the PSMA technology behind PYLARIFY. In 2022, Lantheus purchased Cerveau Technologies for tau imaging agents used in Alzheimer's research. The firm also acquired the rights to flurpiridaz F-18, a next-generation cardiac PET imaging agent, to maintain diagnostic pipeline depth beyond DEFINITY.

Historically pure diagnostics, but the firm is now developing theranostic agents — compounds that pair a diagnostic imaging component with a therapeutic radioactive payload. The progression parallels the industry trend demonstrated by Novartis's Lutathera and Pluvicto. Lantheus is developing LNTH-1070, a radioligand therapy targeting PSMA for prostate cancer treatment, expected to enter Phase 1 trials by late 2025 per standard R&D pipeline guidance from the company.

The name was adopted after the Bristol-Myers Squibb spinout and was likely chosen as a constructed pharmaceutical brand name without pre-existing corporate lineage. It does not reference a historical founder, family, or geographic location. The company retained its Bedford, Massachusetts headquarters and Billerica manufacturing footprint through the rebrand, which separated the entity from its former parent while preserving continuity with existing hospital and radiopharmacy customers.